These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30049953)

  • 1. Clopidogrel Pharmacokinetics in Malaysian Population Groups: The Impact of Inter-Ethnic Variability.
    Zakaria ZH; Fong AYY; Badhan RKS
    Pharmaceuticals (Basel); 2018 Jul; 11(3):. PubMed ID: 30049953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
    Djebli N; Fabre D; Boulenc X; Fabre G; Sultan E; Hurbin F
    Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
    Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
    Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
    Simon T; Bhatt DL; Bergougnan L; Farenc C; Pearson K; Perrin L; Vicaut E; Lacreta F; Hurbin F; Dubar M
    Clin Pharmacol Ther; 2011 Aug; 90(2):287-95. PubMed ID: 21716274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity.
    Duong JK; Nand RA; Patel A; Della Pasqua O; Gross AS
    Pharmacol Res Perspect; 2022 Apr; 10(2):e00946. PubMed ID: 35307978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphism.
    Charfi R; Mzoughi K; Boughalleb M; Hosni H; Kouidhi S; Sfar I; Hammami N; Zaïri I; Limam M; Zedini C; Mrabet A; Klouz A; Gorgi Y; Kharrat M; Baccar H; Trabelsi S
    Tunis Med; 2018 Mar; 96(3):209-218. PubMed ID: 30325490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.
    Hurbin F; Boulenc X; Daskalakis N; Farenc C; Taylor T; Bonneau D; Lacreta F; Cheng S; Sultan E
    J Clin Pharmacol; 2012 Oct; 52(10):1506-15. PubMed ID: 22128201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
    Kobayashi M; Kajiwara M; Hasegawa S
    J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
    Gong IY; Crown N; Suen CM; Schwarz UI; Dresser GK; Knauer MJ; Sugiyama D; DeGorter MK; Woolsey S; Tirona RG; Kim RB
    Eur Heart J; 2012 Nov; 33(22):2856-2464a. PubMed ID: 22374717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
    Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
    Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
    Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
    J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
    Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects.
    Pang YS; Wong LP; Lee TC; Mustafa AM; Mohamed Z; Lang CC
    Br J Clin Pharmacol; 2004 Sep; 58(3):332-5. PubMed ID: 15327595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
    Erlinge D; James S; Duvvuru S; Jakubowski JA; Wagner H; Varenhorst C; Tantry US; Brown PB; Small D; Moser BA; Sundseth SS; Walker JR; Winters KJ; Gurbel PA
    Thromb Haemost; 2014 May; 111(5):943-50. PubMed ID: 24402637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of
    Li H; Zhang YJ; Li MP; Hu XL; Song PY; Peng LM; Ma QL; Tang J; Zhang W; Chen XP
    Front Pharmacol; 2018; 9():1039. PubMed ID: 30283338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the INNOVANCE PFA P2Y assay and its association with CYP2C19 genotypes.
    Kim H; Kim Y; Koh YS; Lee HK; Chae H; Jekarl DW; Lee JM; Shin WS; Kim TH
    Platelets; 2015; 26(2):148-53. PubMed ID: 24617511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of
    Sun H; Qu Q; Chen ZF; Tan SL; Zhou HJ; Qu J; Chen H
    Front Pharmacol; 2016; 7():453. PubMed ID: 27932982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
    Hokimoto S; Akasaka T; Tabata N; Arima Y; Tsujita K; Sakamoto K; Kaikita K; Morita K; Kumagae N; Yamamoto E; Oniki K; Nakagawa K; Ogawa H
    Thromb Res; 2015 Jun; 135(6):1081-6. PubMed ID: 25891840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.